NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 86 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $93,000 | -38.0% | 145,397 | 0.0% | 0.00% | -50.0% |
| Q2 2022 | $150,000 | -45.1% | 145,397 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $273,000 | -61.1% | 145,397 | 0.0% | 0.00% | -60.0% |
| Q4 2021 | $701,000 | -33.3% | 145,397 | 0.0% | 0.01% | -37.5% |
| Q3 2021 | $1,051,000 | -21.7% | 145,397 | 0.0% | 0.01% | -11.1% |
| Q2 2021 | $1,342,000 | -25.0% | 145,397 | 0.0% | 0.01% | -25.0% |
| Q1 2021 | $1,790,000 | -12.7% | 145,397 | 0.0% | 0.01% | -29.4% |
| Q4 2020 | $2,050,000 | +17.5% | 145,397 | 0.0% | 0.02% | -10.5% |
| Q3 2020 | $1,745,000 | -27.7% | 145,397 | 0.0% | 0.02% | -29.6% |
| Q2 2020 | $2,414,000 | +45.9% | 145,397 | 0.0% | 0.03% | +17.4% |
| Q1 2020 | $1,655,000 | -7.6% | 145,397 | 0.0% | 0.02% | +43.8% |
| Q4 2019 | $1,791,000 | +332.6% | 145,397 | 0.0% | 0.02% | +300.0% |
| Q3 2019 | $414,000 | – | 145,397 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
| ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
| EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
| Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
| Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
| Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
| Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
| Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
| PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
| Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |